@article{1274847e0ca943a3acae6a7f93868b82,
title = "Immune recovery and T cell subset analysis during effective treatment with maraviroc",
abstract = "Objectives: Patients treated with maraviroc frequently show high CD4+ T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery. Patients and methods: We studied T cell subsets from frozen peripheral blood mononuclear cells of patients treated with raltegravir, etravirine and either maraviroc (REM, n = 24) or darunavir/ritonavir (RED, n = 17). Results: The two groups showed a similar decrease in activated CD4+ and CD8+ T cells. A greater loss of naive CD4+ T cells and a reduction in cells expressing CXCR4 were observed in REM patients, while RED patients showed a greater loss of cells expressing CCR5. Conclusions: Our findings do not support a role for reduction in activated T cell subsets to explain the greater maraviroc-induced immune recovery. Reduction in CXCR4+CD4+ and higher expression of CCR5+CD4+ T cells might represent a potential protection from non-R5 tropic viral strain overgrowth.",
keywords = "CCR5, CXCR4, Darunavir, HIV, Immune activation, Maraviroc, Naive T cells",
author = "Francesca Cossarini and Andrea Galli and Laura Galli and Alba Bigoloni and Stefania Salpietro and Concetta Vinci and {Della torre}, Liviana and Nicola Gianotti and Vincenzo Spagnuolo and Adriano Lazzarin and Antonella Castagna and Silvia Nozza",
note = "Funding Information: F. C. has received research grants, travel grants or payment for educational grants from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Tibotec (Johnson & Johnson), GlaxoSmithKline, Merck Sharp & Dohme, ViiV Healthcare and Gilead Sciences. L. G. has received payment for educational grants from Bristol-Myers Squibb. N. G. has acted as a consultant to and received research grants from Bristol-Myers Squibb, Abbott, Roche, Boehringer Ingelheim, Pfizer, Virco (Johnson & Johnson), Gilead Sciences and GlaxoSmithKline. V. S. has received payment for educational grants from Bristol-Myers Squibb and Merck Sharp & Dohme. A. L. and A. C. have received grants, travel grants, consultancy fees and payment for educational grants from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, Roche, Tibotec (Johnson & Johnson) and ViiV Healthcare. S. N. has received research grants, consultancy fees, travel grants and payment for educational grants from Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, ViiV Healthcare, Merck Sharp & Dohme, Pfizer, Tibotec (Johnson & Johnson) and Boehringer Ingelheim. All other authors: none to declare.",
year = "2012",
month = oct,
doi = "10.1093/jac/dks216",
language = "English",
volume = "67",
pages = "2474--2478",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "10",
}